Clinical trials: Metastatic Colorectal Cancer, completed
Metastatic Colorectal Cancer
A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer
This is an open label, single-arm, Phase 2 trial to evaluate the anti-tumor activity, safety, and tolerability of Pembrolizumab in combination with azacitidine in subjects with chemo-refractory mCRC without any further standard…
- Trial name
- NCT02260440
- Testing
- Pembrolizumab, Azacitidine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Anuradha Krishnamurthy
Colorectal Cancer
An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer (AXIOM)
This prospective observational study will evaluate the safety and efficacy of Xeloda (capecitabine) administered in monotherapy in patients with metastatic colorectal cancer.
- Trial name
- NCT01697462
- Where
- 5 sites in Serbia
- Volunteers
- 258 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
Cell Membrane Potential Regulates Spatial-Specific Mechanoptosis Resistance and Metastasis in Colorectal Cancer Via Mechanotransduction and the PVR/CD96 Axis
Spatial heterogeneity represents a pivotal driver of therapeutic resistance and metastatic progression in colorectal cancer (CRC).
- Trial name
- NCT07650786
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Ma Tianyi
Metastatic Colorectal Cancer
Recombinant Anti-tumor and Anti-virus Protein for Injection in Treatment of Metastatic Colorectal Cancer
The purpose of this study is to evaluate the efficacy and safety of recombinant anti-tumor and anti-virus protein for injection in treating patients with metastatic colorectal cancer after failure of second-line and more than…
- Trial name
- NCT01386242
- Testing
- Recombinant anti-tumor and anti-virus protein for injection, Saline Injection
- Where
- China
- Volunteers
- 108 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Colorectal Cancer
Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal Cancer
RATIONALE: Drugs used in chemotherapy such as epothilone D work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00077259
- Testing
- epothilone D
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Rectal Neoplasm With Metastasis to the Liver
Simultaneous Versus Staged Resection for Initially Resectable Synchronous Rectal Cancer Liver-limited Metastasis
The purpose of this study is to investigate the safety and efficacy of simultaneous liver resections compared to staged hepatectomies of rectal cancer with liver metastasis and to compare the short and long-term survival between…
- Trial name
- NCT00677586
- Testing
- simultaneous resection of liver metastasis and the rectal primary tumor, staged resection of liver metastasis and the rectal primary tumor
- Volunteers
- 180 people
- Sponsor
- Fudan University
Colorectal Cancer
Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) for Colorectal Cancer in China
S-1 is an oral fluoropyrimidine with demonstrated efficacy on gastric cancer and colorectal cancer. The new regimen with Oxaliplatin and leucovorin is expected to achieve more encouraging efficacy on colorectal cancer.
- Trial name
- SCI-101 (NCT01110941)
- Testing
- S-1, leucovorin, oxaliplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shen Lin
Colorectal Cancer
A Phase Ib Study of Fruquintinib in 3rd Line mCRC
Fruquintinib is a novel oral small molecule compound discovered and developed by Hutchison MediPharma that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent…
- Trial name
- NCT01975077
- Testing
- fruquintinib
- Where
- 2 sites in China
- Volunteers
- 62 people
- Sponsor
- Hutchison Medipharma Limited
Metastatic Colon Cancer
Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response
Colon cancer is one of the most common cancers in France with more than 36,000 new cases per year. Despite significant advances in therapeutic care, the prognosis of colon cancers with metastases remains bad.
- Trial name
- NCT01292356
- Testing
- cetuximab
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Poitiers University Hospital
Colorectal Cancer, Metastasis
Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab
It is a prospective, non-randomized, monocentric study. The purpose of the study is to assess the predictive value of VE-cadherin on the objective tumor response.
- Trial name
- AVECC (NCT01405430)
- Testing
- Bevacizumab + blood samples
- Where
- 2 sites in France
- Volunteers
- 63 people
- Sponsor
- Centre Leon Berard
Colorectal Cancer, Metastatic Cancer
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
RATIONALE: Vaccines made from a gene-modified virus and a person's white blood cells may make the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00103142
- Testing
- falimarev, inalimarev, sargramostim
- Where
- 6 sites in United States
- Volunteers
- 74 people
- Sponsor
- Michael Morse, MD
Lymphomas, Solid Tumors
TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
Background: Methoxyamine hydrochloride (TRC102) is a new cancer treatment drug that may help improve the results of chemotherapy.
- Conditions
- Lymphomas, Solid Tumors, NSCLC, Metastatic Colon Carcinoma
- Trial name
- NCT01851369
- Testing
- TRC102, CT scan, Lomotil
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
Cetuximab Rechallenge Study
To determine the objective overall response of re-treatment with cetuximab-based chemotherapy in patients upon disease progression while under observation, who had previously responded to first-line or second-line treatment with…
- Trial name
- NCT01832467
- Testing
- cetuximab-containing chemotherapy
- Where
- Hong Kong
- Volunteers
- 17 people
- Sponsor
- Chinese University of Hong Kong
Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
Improving Informed Consent for Palliative Chemotherapy
Patients are routinely asked to sign an "informed consent" document prior to starting chemotherapy, indicating they understand the risks and benefits of treatment.
- Conditions
- Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
- Trial name
- NCT02282722
- Testing
- Investigational informed consent for chemotherapy, Usual, standard-of-care informed consent for chemotherapy
- Where
- 8 sites in United States
- Volunteers
- 216 people
- Sponsor
- Dana-Farber Cancer Institute
BRAF V600E, Metastatic Colorectal Cancer
A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.
Encorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase V600E mutant (BRAF V600E) metastatic…
- Trial name
- NAUTICALCRC (NCT05004350)
- Testing
- Encorafenib, Cetuximab, FOLFIRI
- Where
- 34 sites in China
- Volunteers
- 107 people
- Sponsor
- Pierre Fabre Medicament
Non-colorectal Liver Metastasis, Liver Metastasis
National Registry of Hepatic Metastases From Non-Colorectal Cancer"
The investigators designed this observational, retrospective, multicenter study including all patients who underwent surgery for non-colorectal liver metastases between January 2010 and December 2022, with the aim of establishing…
- Conditions
- Non-colorectal Liver Metastasis, Liver Metastasis, Non-neuroendocrine Liver Metastasis, Liver Metastases
- Trial name
- REMENOCOR (NCT07180641)
- Volunteers
- 1,039 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Solid Tumors
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic tyrosine kinase receptors (NTRK). This phase 1 first-in-human study evaluates safety and tolerability of DS-6051b in cancer subjects and…
- Trial name
- NCT02279433
- Testing
- DS6051b
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Nuvation Bio Inc.
Colorectal Cancer
A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer
Bevacizumab has recently been shown to improve survival when combined with chemotherapy in patients with previously untreated metastatic colorectal cancer.
- Trial name
- NCT00483834
- Testing
- Bevacizumab, Irinotecan, Capecitabine
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer Metastatic
Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (DEBIRI).
Background Hepatic metastases of colorectal cancer (MCC) is quite common and is a major source of morbidity and mortality. There has been evidence to show that hepatic arterial chemoembolisation using DC beads (drug eluting…
- Trial name
- NCT02350400
- Testing
- DEBIRI
- Where
- 2 sites in Singapore
- Volunteers
- 5 people
- Sponsor
- Singapore General Hospital
Metastatic Colorectal Cancer
Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies
The purpose of this study is to evaluate the efficacy of S 95005 in patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to standard chemotherapies in terms of Progression-Free Survival rate at 2…
- Trial name
- NCT03274882
- Testing
- S95005
- Where
- 2 sites in Russia
- Volunteers
- 26 people
- Sponsor
- Institut de Recherches Internationales Servier
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.